#### Edgar Filing: Fleming Michael O. - Form 4

Fleming Mic	hael O.										
Form 4											
April 03, 201											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB	PROVAL 3235-0287		
Check thi	s box		Was	shington,	D.C. 20	549			Number:	January 31,	
Subject to Section 16. Form 4 or			F CHANGES IN BENEFICIAL OWN SECURITIES Section 16(a) of the Securities Exchange						Expires: Estimated a burden hour response	2005 verage	
obligatior may conti <i>See</i> Instru 1(b).	inue. Section 17(	a) of the	Public U		ling Con	npany	y Act of	1935 or Section	n		
(Print or Type R	Responses)										
1. Name and Address of Reporting Person <u>*</u> Fleming Michael O.			2. Issuer Name <b>and</b> Ticker or Trading Symbol AMEDISYS INC [AMED]				ng	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (1	Middle)	3. Date of Earliest Transaction (Cne				(Chec	k all applicable	)		
(1			(Month/Day/Year) 04/01/2013					Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer			
			mendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BATON RO	OUGE, LA 70816	i						Form filed by M Person	lore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any	ned n Date, if Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)		d of (D)	5. Amount of Securities6. Ownership Form: DirectBeneficially Owned(D) orOwned Following ReportedIndirect (I)				
G				Code V		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock	04/01/2013			А	6,501 (1)	А	\$0	18,349	D		
Common Stock	04/01/2013			F	832	D	\$ 10.96	17,517	D		
Common Stock								679 <u>(2)</u>	Ι	Through 401(k) Plan	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form

#### Edgar Filing: Fleming Michael O. - Form 4

# displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and <i>J</i> Underlying S (Instr. 3 and	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	<u>(3)</u>	04/01/2013		А	6,501	(3)	04/01/2018	Common Stock	6,501

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
1	Director	10% Owner	Officer	Other		
Fleming Michael O. 5959 S. SHERWOOD FOREST BLVD. BATON ROUGE, LA 70816			Chief Medical Officer			
Signatures						

Celeste R. Peiffer on behalf of Michael O. Fleming pursuant to a Power of	04/03/2013
Attorney	04/05/2015
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares awarded are subject to service-based vesting conditions and will vest in equal, one-third increments on each of April 1, 2014, April 1, 2015 and April 1, 2016, provided that the reporting person remains employed by the issuer on each such date.
- (2) Includes 282 shares acquired by the reporting person under the Amedisys, Inc. 401(k) Plan since the date of the reporting person's last report.

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Amedisys, Inc. (the "Company") common stock with vesting conditions based on the Company's compound total shareholder return (TSR) over defined measurement periods. The

(3) number of shares of Company common stock earned upon vesting of the RSUs will (i) depend on (a) the actual compound TSR achieved and (b) the applicable measurement period and (ii) will range from 17% to 160% of the number of RSUs reported in Column 5 of Table II, assuming the reporting person remains continuously employed by the Company through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.